Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy: Randomized Clinical Control Trial

Chronic insertional Achilles tendinopathy is an overuse condition with prolonged recovery, where outcomes after traditional loading programs can be variable. Your protocol builds on standard rehabilitation principles (progressive loading, symptom-guided activity modification, and graded return to function) while testing whether blood flow restriction (BFR) can improve rehabilitation efficiency by enabling meaningful neuromuscular adaptation at lower external loads. This rationale aligns with emerging mechanistic and clinical evidence that low-load BFR can drive clinically relevant adaptations while reducing mechanical stress on painful tissues.

This study is designed as a two-arm randomized controlled trial conducted in an outpatient rehabilitation setting, comparing standard-of-care rehabilitation alone versus standard-of-care rehabilitation augmented with BFR. The overarching hypothesis is that adding BFR to a structured rehabilitation pathway will yield superior improvements in pain-related disability and function (tracked with validated clinical instruments) and will translate into better performance on functional tasks commonly affected in Achilles tendinopathy (e.g., endurance and hopping tolerance).

To ensure diagnostic precision and a clinically homogeneous sample, the protocol specifies confirmation of chronic insertional Achilles tendinopathy using a combination of symptom chronicity and exam/imaging features, including localized tenderness near the calcaneal insertion, functional provocation testing, and imaging evidence of structural tendon change (ultrasound or MRI). These steps are intended to reduce misclassification and improve interpretability of treatment effects in a condition with multiple pain generators around the posterior heel.

Randomization is structured to enhance baseline balance on variables that can meaningfully influence rehabilitation response. Specifically, allocation is stratified by baseline activity level (Cincinnati Sports Activity Scale) and by baseline clinical severity using a VISA-A threshold (<50 vs ≥50). The target sample size is 40 participants (20 per group), selected to detect a clinically meaningful improvement on the VISA-A (minimal clinically important difference of 10 points) with 90% power and α=0.05, while incorporating an allowance for attrition. The analysis plan is aligned with CONSORT expectations for rehabilitation trials and anticipates covariate-adjusted mixed modeling to evaluate group-by-time effects.

Intervention delivery follows a pragmatic rehabilitation model. The standard-care arm uses established physical therapy approaches-progressive loading (including eccentric-focused strategies), education on activity modification, and a staged return-to-function progression-implemented and advanced based on symptoms and functional tolerance. In the BFR-augmented arm, the same rehabilitation exercises are performed while applying BFR using Smart Tools Plus (LLC, USA) with limb sleeves and cuffs placed proximally on the thigh. Limb occlusion pressure (LOP) is set individually immediately prior to exercise, and the protocol applies 40-80% of LOP during the exercise sets. Participants are monitored throughout for adverse signs/symptoms, consistent with published evidence that BFR-when appropriately screened, dosed, and supervised-has an acceptable safety profile in musculoskeletal rehabilitation populations.